Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q86TM3 (
cage
)
29,987
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Asporin has been reported as a tumor suppressor in breast cancer, while
asporin
-activated invasion has been described in gastric cancer. According to our in silico search, high
asporin
expresion associates with significantly better relapse free survival (RFS) in patients with low-grade tumors but RFS is significantly worse in patients with grade 3 tumors. In line with other studies, we have confirmed
asporin
expression by RNA scope in situ hybridization in
cancer associated
fibroblasts. We have also found
asporin
expression in the Hs578T breast cancer cell line which we confirmed by quantitative RT-PCR and western blotting. From multiple testing, we found that
asporin
can be downregulated by bone morphogenetic protein 4 while upregulation may be facilited by serum-free cultivation or by three dimensional growth in stiff Alvetex scaffold. Downregulation by shRNA inhibited invasion of Hs578T as well as of CAFs and T47D cells. Invasion of
asporin
-negative MDA-MB-231 and BT549 breast cancer cells through collagen type I was enhanced by recombinant
asporin
. Besides other investigations, large scale analysis of aspartic acid repeat polymorphism will be needed for clarification of the
asporin
dual role in progression of breast cancer.
...
PMID:The dual role of asporin in breast cancer progression. 2740 32
Tumor progression to metastasis is not cancer cell autonomous, but rather involves the interplay of multiple cell types within the tumor microenvironment. Here we identify
asporin
(
ASPN
) as a novel, secreted mesenchymal stromal cell (MSC) factor in the tumor microenvironment that regulates metastatic development. MSCs expressed high levels of
ASPN
, which decreased following lineage differentiation.
ASPN
loss impaired MSC self-renewal and promoted terminal cell differentiation. Mechanistically, secreted
ASPN
bound to BMP-4 and restricted BMP-4-induced MSC differentiation prior to lineage commitment.
ASPN
expression was distinctly conserved between MSC and
cancer-associated
fibroblasts (CAF).
ASPN
expression in the tumor microenvironment broadly impacted multiple cell types. Prostate tumor allografts in
ASPN
-null mice had a reduced number of tumor-associated MSCs, fewer cancer stem cells, decreased tumor vasculature, and an increased percentage of infiltrating CD8
+
T cells.
ASPN
-null mice also demonstrated a significant reduction in lung metastases compared with wild-type mice. These data establish a role for
ASPN
as a critical MSC factor that extensively affects the tumor microenvironment and induces metastatic progression. SIGNIFICANCE: These findings show that
asporin
regulates key properties of mesenchymal stromal cells, including self-renewal and multipotency, and
asporin
expression by reactive stromal cells alters the tumor microenvironment and promotes metastatic progression.
...
PMID:Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression. 3112 87